dihydroergotamine mesylate Latest Research Papers

Dihydroergotamine Mesylate Injection

10.31003/uspnf_m26090_03_01 ◽

2021 ◽

Keyword(s):

Dihydroergotamine Mesylate

Download Full-text

Dihydroergotamine Mesylate

10.31003/uspnf_m26080_03_01 ◽

2021 ◽

Keyword(s):

Dihydroergotamine Mesylate

Download Full-text

STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD ® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients

Headache The Journal of Head and Face Pain ◽

10.1111/head.14184 ◽

2021 ◽

Author(s):

Timothy R. Smith ◽

Paul Winner ◽

Sheena K. Aurora ◽

Maria Jeleva ◽

Jasna Hocevar‐Trnka ◽

...

Keyword(s):

Acute Treatment ◽

Adult Patients ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Dihydroergotamine Mesylate

Download Full-text

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects

Headache The Journal of Head and Face Pain ◽

10.1111/head.13737 ◽

2020 ◽

Vol 60 (4) ◽

pp. 701-712 ◽

Cited By ~ 1

Author(s):

Detlef Albrecht ◽

Mic Iwashima ◽

Debbie Dillon ◽

Stuart Harris ◽

Jeff Levy

Keyword(s):

Healthy Adult ◽

Phase 1 ◽

Open Label ◽

Bioavailability Study ◽

Comparative Bioavailability ◽

Dihydroergotamine Mesylate ◽

Comparative Bioavailability Study

Download Full-text

Dihydroergotamine Mesylate

10.32388/v7uh2z ◽

2020 ◽

Author(s):

Keyword(s):

Dihydroergotamine Mesylate

Download Full-text

Development and in vitro/in vivo evaluation of dihydroergotamine mesylate loaded maltodextrin-pullulan sublingual films

Drug Development and Industrial Pharmacy ◽

10.1080/03639045.2019.1578788 ◽

2019 ◽

Vol 45 (6) ◽

pp. 914-921 ◽

Cited By ~ 3

Author(s):

Ozgur Esim ◽

Cansel K. Ozkan ◽

Sevinc Kurbanoglu ◽

Alper Arslan ◽

Cetin Tas ◽

...

Keyword(s):

In Vivo Evaluation ◽

Dihydroergotamine Mesylate

Download Full-text

STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects

Headache The Journal of Head and Face Pain ◽

10.1111/head.13476 ◽

2019 ◽

Vol 59 (3) ◽

pp. 394-409 ◽

Cited By ~ 5

Author(s):

Stephen B. Shrewsbury ◽

Maria Jeleva ◽

Kelsey H. Satterly ◽

Jason Lickliter ◽

John Hoekman

Keyword(s):

Healthy Adult ◽

Phase 1 ◽

Open Label ◽

Bioavailability Study ◽

Comparative Bioavailability ◽

Dihydroergotamine Mesylate ◽

Comparative Bioavailability Study

Download Full-text

Dihydroergotamine Mesylate

Pediatric Injectable Drugs ◽

10.37573/9781585285402.083 ◽

2018 ◽

pp. 300-303

Keyword(s):

Dihydroergotamine Mesylate

Download Full-text

Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy

Journal of Controlled Release ◽

10.1016/j.jconrel.2017.10.021 ◽

2017 ◽

Vol 268 ◽

pp. 159-165 ◽

Cited By ~ 22

Author(s):

Cetin Tas ◽

Jessica C. Joyce ◽

Hiep X. Nguyen ◽

Padmanabhan Eangoor ◽

Jennifer S. Knaack ◽

...

Keyword(s):

Acute Migraine ◽

Migraine Therapy ◽

Microneedle Patch ◽

Dihydroergotamine Mesylate

Download Full-text

MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2012.711319 ◽

2012 ◽

Vol 13 (13) ◽

pp. 1961-1968 ◽

Cited By ~ 13

Author(s):

Stephen Silberstein

Keyword(s):

Acute Treatment ◽

Dihydroergotamine Mesylate

Download Full-text

dihydroergotamine mesylate
Recently Published Documents

TOTAL DOCUMENTS

H-INDEX

Dihydroergotamine Mesylate Injection

Dihydroergotamine Mesylate

STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD ® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects

Dihydroergotamine Mesylate

Development and in vitro/in vivo evaluation of dihydroergotamine mesylate loaded maltodextrin-pullulan sublingual films

STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects

Dihydroergotamine Mesylate

Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy

MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine

Export Citation Format

dihydroergotamine mesylateRecently Published Documents

TOTAL DOCUMENTS

H-INDEX

Dihydroergotamine Mesylate Injection

Dihydroergotamine Mesylate

STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD ® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects

Dihydroergotamine Mesylate

Development and in vitro/in vivo evaluation of dihydroergotamine mesylate loaded maltodextrin-pullulan sublingual films

STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects

Dihydroergotamine Mesylate

Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy

MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine

dihydroergotamine mesylate
Recently Published Documents